title: [Study on the sensitivity of leukemic cells to arsenic trioxide enhanced by targeted suppression of mIRNA-21].
abstract: OBJECTIVE
  To study the effect of antisense oligonucleotide targeted on miRNA-21 (AMO-miR-21) for enhancing the arsenic trioxide (As2O3) sensitivity of leukemic K562 cells and its possible acting mechanism.
  
  
  METHODS
  Chemosynthetic AMO-miR-21 was transfected to K562 cells using Lipofectamine TM 2000. The inhibitory effects of As2O3 and AMO-miR-21, used singly or in combining, on cell proliferation were detected by MTT, their inhibition rate and IC50 were calculated. Cell cycle and apoptosis were assessed with PI stain; expression of miRNA-21 in cells was detected quantitatively by real-time PCR, and the potential target gene PDCD, protein expression was detected by immuno-fluorimetry.
  
  
  RESULTS
  Used in combining with AMO-miR-21, the IC50 of As2O3, could be lowered from 2.1 micromol/L to 1.23 micromol/L, and the sensitivity of cells to As2O3 increased to 1.78-fold; with the amount of apoptotic cells increased significantly. Transfection with AMO-miR-21 alone could downregulate the expression of miRNA-21 in cells (P < 0.01), and up-regulate PDCD, protein expression level significantly.
  
  
  CONCLUSIONS
  Combined use of AMO-miR-21 and As2O3 could increase the sensitivity of K562 cells to As2O3, which provides a novel potential approach for treatment of leukemia. AMO-miR-21 realizes it anti-tumor action by way of targeted inhibition on miRNA-21, and further up-regulates the expression of anti-tumor gene PDCD4.
authors.affiliation: Department of Biochemistry and Molecular Biology, Medical College of Jinan University, College of Jinan University, Guangzhou.
authors.forename: Yu-min
authors.initials: YM
authors.lastname: Li
authors.forename: Jing-yi
authors.initials: JY
authors.lastname: Gu
authors.forename: Xue-jiao
authors.initials: XJ
authors.lastname: Zhu
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D051017:Apoptosis Regulatory Proteins / Q000378:metabolism; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000494:pharmacology*; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D020014:K562 Cells; D035683:MicroRNAs / Q000187:drug effects*; D016376:Oligonucleotides, Antisense / Q000494:pharmacology; D010087:Oxides / Q000494:pharmacology*; D016601:RNA-Binding Proteins / Q000378:metabolism; D014162:Transfection
chemical_list: D000970:Antineoplastic Agents; D051017:Apoptosis Regulatory Proteins; D001152:Arsenicals; C524940:MIRN21 microRNA, human; D035683:MicroRNAs; D016376:Oligonucleotides, Antisense; D010087:Oxides; C114487:PDCD4 protein, human; D016601:RNA-Binding Proteins; D000077237:Arsenic Trioxide